mProX™ Human CD22 Stable Cell Line

Product Information

Target Family

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;OCI-Ly8

Target Classification

CD Cell Lines

Target Research Area

Cancer Research

Related Diseases

Refractory Hairy Cell Leukemia; Refractory Hematologic Cancer

Gene ID

Human:933

UniProt ID

Human:P20273

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD22 has various applications in cancer research and treatment. One application is in improving the cytotoxicity of chimeric antigen receptor (CAR)-T cell therapies against low-antigen cancers. By engineering CARs targeting CD22 and including intrinsically disordered regions (IDRs), CAR-T cells can exhibit enhanced membrane-proximal signaling, leading to increased release of cytotoxic factors and improved killing activity against low antigen-expressing cancer cells. This approach broadens the application of CAR-T therapy to cancers with low antigen expression. Another application of CD22 is in the normalization of small extracellular vesicle (sEV) cargo in human cancer. sEVs in the blood of cancer patients contain higher amounts of tumor markers, including miRNAs. CD22 can serve as a reliable endogenous control for measuring sEV-miRNA content, allowing for standardized and consistent measurements in cancer liquid biopsy. Additionally, CD22 is targeted in sequential CAR-T cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukemia. This approach involves initially infusing CD19-directed CAR T cells, followed by CD22-directed CAR T-cell infusion after achieving minimal residual disease-negative complete remission. This sequential strategy has shown deep and sustained responses with an acceptable toxicity profile, providing potential long-term benefits for children with this condition. However, it is important to note that there can be side effects associated with CAR-T cell therapy, such as cytomegalovirus (CMV) infection/reactivation. CMV infection can occur in patients long after receiving anti-CD19/22 CAR-T cell therapy and can induce fatal pneumonia. Therefore, monitoring and managing viral infections or reactivations is crucial in patients receiving CAR-T cell infusion. Finally, CD22 has also been studied in the context of the impact of the COVID-19 pandemic on the diagnosis of colorectal cancer within a population-based organized screening program. The pandemic resulted in delays in screening and colonoscopy, but it did not significantly reduce participation, adherence to colonoscopy, or the diagnostic yield of colonoscopy.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CD22 Stable Cell Line (S01YF-1023-PY225). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Williams (Verified Customer)

What is the role of CD22 in B cell signaling? Jul 11 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

CD22 acts as a regulator of B cell receptor signaling, modulating immune responses. It interacts with proteins like SHP-1 to control B cell activation and tolerance. Jul 11 2022

chat Skyler Jones (Verified Customer)

How does CD22-targeted therapy work in leukemia? May 01 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

CD22-targeted therapies, including CAR T-cell therapy, have shown promise in treating leukemia, especially in cases where CD19-targeted therapies have failed. May 01 2020

Published Data

Fig.1 Exogenously expressed CD22 protein was detected within CD22-deleted OCI-Ly8 cells through flow cytometry analysis.

Following the reconstitution of CD22-deleted OCI-Ly8 cells with CD22 FL and CD22 Δex2-6, it was observed that cells expressing CD22 Δex2-6 exhibited an absence of flow cytometric staining when subjected to various anti-CD22 antibodies.

Ref: Zheng, Sisi, et al. "Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies." Blood cancer discovery 3.2 (2022): 103-115.

Pubmed: 35015683

DOI: 10.1158/2643-3230.BCD-21-0087

Research Highlights

Burdiel, Miranda. et al. "MiR-151a: a robust endogenous control for normalizing small extracellular vesicle cargo in human cancer." Biomarker research, 2023.
The study conducted by the authors aimed to identify suitable endogenous controls for the measurement of small extracellular vesicle (sEV)-miRNA content in liquid biopsies of cancer patients. They performed a comprehensive analysis and identified three miRNAs as potential normalizers from a panel of nine in six human lung and ovarian cancer cell lines. The normalizers were then tested on 26 additional cancer cell lines from nine different tumor types undergoing chemotherapy or radiotherapy, as well as 242 prospective samples from three human tumor types. Results showed that miR-151a had minimal variability compared to the commonly used control miR-16, making it a reliable and consistent normalizer for sEV-miRNA content measurement in cancer liquid biopsies.
Burdiel, Miranda. et al. "MiR-151a: a robust endogenous control for normalizing small extracellular vesicle cargo in human cancer." Biomarker research, 2023.
Pubmed: 37864266 DOI: 10.1186/s40364-023-00526-0

Pan, Jing. et al. "Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study." The Lancet. Oncology, 2023.
In the treatment of relapsed or refractory B-cell acute lymphocytic leukemia in children, relapses are a common occurrence following CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The objective of this study is to evaluate the efficacy and safety of sequential treatments using CD19-directed and CD22-directed CAR T-cells. The results of this study may provide insight into potential treatment strategies for these patients.
Pan, Jing. et al. "Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study." The Lancet. Oncology, 2023.
Pubmed: 37863088 DOI: 10.1016/S1470-2045(23)00436-9